Navigation Links
Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine
Date:10/27/2011

BOSTON and CAMBRIDGE, Mass., Oct. 27, 2011 /PRNewswire/ -- A potentially groundbreaking approach to predicting cancer patient response to certain treatments is described today in the electronic version of Science Magazine.  The paper describing the technology, called BH3 profiling, is published by Dr. Anthony Letai and colleagues at Boston's Dana Farber Cancer Institute. The technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to gauge ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs.

Letai explained, "Our experiments with BH3 profiling demonstrate that understanding of the pretreatment tumor mitochondria can offer valuable predictive information about clinical response.  As such, BH3 profiling has the potential to personalize therapy for cancer patients by predicting the quality of a patient's response to a given treatment."

This capability is in line with an FDA draft guidance document issued in July of this year calling for companion diagnostic tests for targeted therapies.

The job of commercializing this assay has been assumed by Cambridge, MA based Eutropics Pharmaceuticals, where Dr. Letai serves as chair of the SAB. Eutropics has exclusively licensed the technology from Dana Farber. Currently the test is being developed by the company for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients.

"Eutropics is uniquely positioned to provide this important test that will help cancer patients receive the appropriate treatments," said Dr. Michael Cardone, CEO of Eutropics Pharmaceuticals.  Eutropics' effort to commercialize the BH3 profiling assay is being done in collaboration with Dana Farber Cancer Institute, University of Massachusetts Medical School, M.D. Anderson Cancer Center, and the National Cancer Institute.

About the company:

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by developing novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology.  This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.  The company is supported by private investors, grants from the NCI, and a loan from the Massachusetts Life Sciences Center.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
4. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
5. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
6. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
7. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
8. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
9. Groundbreaking Ceremony in Port-au-Prince, Haiti for FilterPure Water Filtration Factory
10. Sensitechs Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):